Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) EBITDA (2016 - 2025)

Historic EBITDA for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $22.9 million.

  • Veracyte's EBITDA rose 9094.62% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 20516.99%. This contributed to the annual value of $16.1 million for FY2024, which is 11881.46% up from last year.
  • According to the latest figures from Q3 2025, Veracyte's EBITDA is $22.9 million, which was up 9094.62% from -$5.3 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's EBITDA registered a high of $22.9 million during Q3 2025, and its lowest value of -$41.9 million during Q1 2021.
  • Over the past 5 years, Veracyte's median EBITDA value was -$9.0 million (recorded in 2021), while the average stood at -$9.0 million.
  • As far as peak fluctuations go, Veracyte's EBITDA crashed by 55511.07% in 2023, and later surged by 16237.11% in 2025.
  • Quarter analysis of 5 years shows Veracyte's EBITDA stood at -$12.3 million in 2021, then surged by 56.05% to -$5.4 million in 2022, then tumbled by 555.11% to -$35.5 million in 2023, then skyrocketed by 111.76% to $4.2 million in 2024, then soared by 449.6% to $22.9 million in 2025.
  • Its EBITDA stands at $22.9 million for Q3 2025, versus -$5.3 million for Q2 2025 and $2.9 million for Q1 2025.